【结 构 式】 |
【分子编号】31642 【品名】(5-methyl-2,3-dihydro-1H-indol-7-yl)(phenyl)methanone 【CA登记号】 |
【 分 子 式 】C16H15NO 【 分 子 量 】237.30124 【元素组成】C 80.98% H 6.37% N 5.9% O 6.74% |
合成路线1
该中间体在本合成路线中的序号:(III)The condensation of 5-methylindoline (I) with benzonitrile (II) by means of BCl3 and AlCl3 in dichloroethane gives the 7-benzoyl-5-methylindoline (III), which is cyclized with glycine methyl ester (IV) in pyridine yielding the tricyclic pyrrolobenzodiazepinone (V). The reaction of (V) with isoamyl nitrite and potassium tert-butoxide in THF affords the oxime (VI), which is reduced with H2 over Ru/C in methanol providing the racemic amine (VII). The optical resolution of (VII) with N-acetyl-L-phenylalanine gives the desired isomer (VIII), which is finally condensed with pyridine-4-carboxylic acid (IX) by means of O-[1-(ethoxycarbonyl)-1-cyanomethyleneamino]-N,N,N',N'-tetramethyluronium tetrafluoroborate (TOTU) and DIEA in dichloromethane.
【1】 Andrianjara, C.R.; Auclair, E.; Pascal, Y.; et al.; Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: Novel PDE4 inhibitors. Bioorg Med Chem Lett 2000, 10, 1, 35. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 31641 | 5-methylindoline | C9H11N | 详情 | 详情 | |
(II) | 25904 | benzonitrile | 100-47-0 | C7H5N | 详情 | 详情 |
(III) | 31642 | (5-methyl-2,3-dihydro-1H-indol-7-yl)(phenyl)methanone | C16H15NO | 详情 | 详情 | |
(IV) | 17568 | methyl 2-aminoacetate | C3H7NO2 | 详情 | 详情 | |
(V) | 31643 | 9-methyl-1-phenyl-6,7-dihydro[1,4]diazepino[6,7,1-hi]indol-4(3H)-one | C18H16N2O | 详情 | 详情 | |
(VI) | 31644 | 9-methyl-1-phenyl-6,7-dihydro[1,4]diazepino[6,7,1-hi]indole-3,4-dione 3-oxime | C18H15N3O2 | 详情 | 详情 | |
(VII) | 31645 | 3-amino-9-methyl-1-phenyl-6,7-dihydro[1,4]diazepino[6,7,1-hi]indol-4(3H)-one | C18H17N3O | 详情 | 详情 | |
(VIII) | 31646 | (3R)-3-amino-9-methyl-1-phenyl-6,7-dihydro[1,4]diazepino[6,7,1-hi]indol-4(3H)-one | C18H17N3O | 详情 | 详情 | |
(IX) | 25028 | isonicotinic acid | 55-22-1 | C6H5NO2 | 详情 | 详情 |